Medicare criticized for high spending on Alzheimer’s drugs; related shortages noted
Stat News highlights that Medicare has missed the mark on controlling spending for Alzheimer’s medications, describing the costs as unsustainable. The accompanying newsletter (Stat’s “Pharmalittle”) mentions the same Medicare issue while also flagging unrelated shortages such as estrogen patches, showing a broader context of pharmaceutical supply challenges.